3E1S
 
 | | Structure of an N-terminal truncation of Deinococcus radiodurans RecD2 | | 分子名称: | Exodeoxyribonuclease V, subunit RecD | | 著者 | Saikrishnan, K, Griffiths, S.P, Cook, N, Court, R, Wigley, D.B. | | 登録日 | 2008-08-04 | | 公開日 | 2008-08-19 | | 最終更新日 | 2024-02-21 | | 実験手法 | X-RAY DIFFRACTION (2.2 Å) | | 主引用文献 | DNA binding to RecD: role of the 1B domain in SF1B helicase activity.
Embo J., 27, 2008
|
|
1C14
 | | CRYSTAL STRUCTURE OF E COLI ENOYL REDUCTASE-NAD+-TRICLOSAN COMPLEX | | 分子名称: | ENOYL REDUCTASE, NICOTINAMIDE-ADENINE-DINUCLEOTIDE, TRICLOSAN | | 著者 | Qiu, X, Janson, C, Court, R, Smyth, M, Payne, D, Abdel-Meguid, S. | | 登録日 | 1999-07-20 | | 公開日 | 2000-07-20 | | 最終更新日 | 2024-02-07 | | 実験手法 | X-RAY DIFFRACTION (2 Å) | | 主引用文献 | Molecular basis for triclosan activity involves a flipping loop in the active site.
Protein Sci., 8, 1999
|
|
3GP8
 | | Crystal structure of the binary complex of RecD2 with DNA | | 分子名称: | 5'-D(*TP*TP*TP*TP*TP*T*TP*TP*TP*TP*TP*TP*TP*T)-3', Exodeoxyribonuclease V, subunit RecD, ... | | 著者 | Saikrishnan, K, Cook, N, Wigley, D.B. | | 登録日 | 2009-03-23 | | 公開日 | 2009-06-16 | | 最終更新日 | 2023-09-06 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | Mechanistic basis of 5'-3' translocation in SF1B helicases.
Cell(Cambridge,Mass.), 137, 2009
|
|
3K70
 | |
3GPL
 | | Crystal structure of the ternary complex of RecD2 with DNA and ADPNP | | 分子名称: | 5'-D(*T*TP*TP*TP*TP*TP*TP*T)-3', Exodeoxyribonuclease V, subunit RecD, ... | | 著者 | Saikrishnan, K, Cook, N, Wigley, D.B. | | 登録日 | 2009-03-23 | | 公開日 | 2009-06-16 | | 最終更新日 | 2023-09-06 | | 実験手法 | X-RAY DIFFRACTION (2.5 Å) | | 主引用文献 | Mechanistic basis of 5'-3' translocation in SF1B helicases.
Cell(Cambridge,Mass.), 137, 2009
|
|
6HXW
 | | structure of human CD73 in complex with antibody IPH53 | | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 5'-nucleotidase, IPH53 heavy chain, ... | | 著者 | Roussel, A, Amigues, B. | | 登録日 | 2018-10-18 | | 公開日 | 2019-08-28 | | 最終更新日 | 2020-07-29 | | 実験手法 | X-RAY DIFFRACTION (2.78 Å) | | 主引用文献 | Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies.
Cell Rep, 27, 2019
|
|
